Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25273
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChételat, Gaël-
dc.contributor.authorArbizu, Javier-
dc.contributor.authorBarthel, Henryk-
dc.contributor.authorGaribotto, Valentina-
dc.contributor.authorLaw, Ian-
dc.contributor.authorMorbelli, Silvia-
dc.contributor.authorvan de Giessen, Elsmarieke-
dc.contributor.authorAgosta, Federica-
dc.contributor.authorBarkhof, Frederik-
dc.contributor.authorBrooks, David J-
dc.contributor.authorCarrillo, Maria C-
dc.contributor.authorDubois, Bruno-
dc.contributor.authorFjell, Anders M-
dc.contributor.authorFrisoni, Giovanni B-
dc.contributor.authorHansson, Oskar-
dc.contributor.authorHerholz, Karl-
dc.contributor.authorHutton, Brian F-
dc.contributor.authorJack, Clifford R-
dc.contributor.authorLammertsma, Adriaan A-
dc.contributor.authorLandau, Susan M-
dc.contributor.authorMinoshima, Satoshi-
dc.contributor.authorNobili, Flavio-
dc.contributor.authorNordberg, Agneta-
dc.contributor.authorOssenkoppele, Rik-
dc.contributor.authorOyen, Wim J G-
dc.contributor.authorPerani, Daniela-
dc.contributor.authorRabinovici, Gil D-
dc.contributor.authorScheltens, Philip-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorZetterberg, Henrik-
dc.contributor.authorDrzezga, Alexander-
dc.date2020-11-
dc.date.accessioned2020-11-10T03:07:41Z-
dc.date.available2020-11-10T03:07:41Z-
dc.date.issued2020-11-
dc.identifier.citationThe Lancet. Neurology 2020; 19(11): 951-962en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25273-
dc.description.abstractVarious biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a diagnostic algorithm with optimal timepoints for these PET biomarkers, also taking into account evidence from other biomarkers, for early and differential diagnosis of neurodegenerative diseases that can lead to dementia. We propose three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and 18F-FDG-PET are placed at different positions in the order of diagnostic evaluations, depending on clinical presentation. We hope that this algorithm can support diagnostic decision making in specialist clinical settings with access to these biomarkers and might stimulate further research towards optimal diagnostic strategies.en
dc.language.isoeng
dc.titleAmyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Lancet. Neurologyen
dc.identifier.affiliationNormandie Université, Université de Caen, Institut National de la Santé et de la Recherche Médicale, Unité 1237, Groupement d'Intérêt Public Cyceron, Caen, France.en
dc.identifier.affiliationSchool of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine, University of Navarra, Clinica Universidad de Navarra, Pamplona, Spainen
dc.identifier.affiliationDepartment of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germanyen
dc.identifier.affiliationDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals and NIMTlab, Geneva University, Geneva, Switzerlanden
dc.identifier.affiliationDepartment of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmarken
dc.identifier.affiliationNuclear Medicine Unit, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italyen
dc.identifier.affiliationDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlandsen
dc.identifier.affiliationNeuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Istituto di Ricovero e Cura a Carattere, San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italyen
dc.identifier.affiliationDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Institutes of Neurology and Healthcare Engineering, University College London, London, UKen
dc.identifier.affiliationInstitute of Neuroscience, Newcastle University, Newcastle, UK; Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmarken
dc.identifier.affiliationAlzheimer's Association, Chicago, IL, USAen
dc.identifier.affiliationCentre des Maladies Cognitives et Comportementales, University Hospital of Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne-Université, Paris, Franceen
dc.identifier.affiliationCenter for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Norway, Oslo; Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norwayen
dc.identifier.affiliationMemory Clinic, Department of Rehabilitation and Geriatrics, Geneva University and University Hospitals, Geneva, Switzerlanden
dc.identifier.affiliationClinical Memory Research Unit, Lund University, Malmö, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Swedenen
dc.identifier.affiliationWolfson Molecular Imaging Centre, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UKen
dc.identifier.affiliationInstitute of Nuclear Medicine, University College London, London, UKen
dc.identifier.affiliationDepartment of Radiology, Mayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlandsen
dc.identifier.affiliationHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USAen
dc.identifier.affiliationDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT, USAen
dc.identifier.affiliationUO Clinica Neurologica, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Child and Mother Health, University of Genoa, Genova, Italyen
dc.identifier.affiliationDepartment of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Swedenen
dc.identifier.affiliationDepartment of Neurology, Alzheimer Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Clinical Memory Research Unit, Lund University, Lund, Swedenen
dc.identifier.affiliationHumanitas University and Humanitas Clinical and Research Center, Department of Nuclear Medicine, Milan, Italy; Rijnstate, Department of Radiology and Nuclear Medicine, Arnhem, Netherlands; Radboud UMC, Department of Radiology and Nuclear Medicine, Nijmegen, Netherlandsen
dc.identifier.affiliationVita-Salute San Raffaele University, Nuclear Medicine Unit, San Raffaele Hospital, Division of Neuroscience San Raffaele Scientific Institute, Milan, Italyen
dc.identifier.affiliationDepartments of Neurology, Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USAen
dc.identifier.affiliationDepartment of Neurology, Alzheimer Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlandsen
dc.identifier.affiliationDepartment of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at University College London, London, UKen
dc.identifier.affiliationDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; German Center for Neurodegenerative Diseases, Bonn-Cologne, Germany; Institute of Neuroscience and Medicine, Molecular Organization of the Brain, Forschungszentrum Jülich, Germanyen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.doi10.1016/S1474-4422(20)30314-8en
dc.type.contentTexten
dc.identifier.pubmedid33098804
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Jan 15, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.